Why the study?
Does IRF4 modulation affect pathological cardiac hypertrophy in response to pressure overload?
Population
Transgenic mouse model with cardiac-specific overexpression of IRF4, IRF4 knockout mice, and ex vivo…
Comparison
Aortic banding for 4 to 8 weeks in mice… vs Control mice/hearts and untreated cardiomyocytes
Design
Preclinical
Follow-up
4 to 8 weeks
Authors
Loading...
IRF4-CREB modulation alters hypertrophy in pressure-overload models; hypothesis-generating for therapeutic targeting pending human studies.
Does IRF4 modulation affect pathological cardiac hypertrophy in response to pressure overload?
IRF4 functions as a necessary modulator of the hypertrophic response by activating CREB transcription, suggesting it may be a novel therapeutic target for pathological cardiac hypertrophy and heart failure.
Jiang et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: